CELEXT07 a new botanical agent for grey
mold;
Mondias to target small fruit cultivation market
MONTREAL, Dec. 5, 2018 /CNW/ - Mondias Natural
Products Inc ("Mondias" or "NHP"), (TSXV:
NHP), updates the market on results after the completion of a
second NSERC ENGAGE funded research project with McGill University on its innovative botanical agent
CELEXT07. The studies demonstrated that CELEXT07 when used as
a soil drench agent at a single dose or repeated doses
significantly reduced Grey Mold (Botrytis cinereal) lesions on two
horticultural plants, tomato and lettuce.
![Logo: Mondias Natural Products Inc. (CNW Group/Mondias Natural Products Inc.) Logo: Mondias Natural Products Inc. (CNW Group/Mondias Natural Products Inc.)](https://mma.prnewswire.com/media/793901/Mondias_Natural_Products_Inc__Mondias_Provides_Update_on_Natural.jpg)
Large scale greenhouse trials evaluating the efficacy of
CELEXT07 extracts in disease suppression of Grey Mold were
performed on two horticultural plants. The infection from Grey Mold
on non-detached leaves of soil-drenched plants was significantly
reduced. Compared to control treatment, disease index
decreased by almost 90%. Other experiments demonstrated the ability
of CELEXT07 to significantly reduce Grey Mold lesions on detached
leaves (P <0.05). The study also showed that from an
economical point of view, a single dose treatment was
sufficient.
Grey Mold is a plant pathogen that causes significant
devastating diseases on over 500 plant species (including fruits
and vegetables). These infections result in annual economic
losses between $10 billion to
$100 billion worldwide (L. Hua et al.
2018). In addition, about one-third of the food produced worldwide
for human consumption is lost after harvest (Gastavsson et al.,
2011). Infections by fungus are a major factor of food
wastage and Grey Mold is considered one of the most important
postharvest decays of fresh fruit and vegetables (Romanazzi et al.,
2016).
Mondias' research will pave the road for the commercialization
of a new botanical-based agent for prevention and management of
Grey Mold infections in horticultural crops as well as the
prevention of lesions on harvested crops. The corporation
plans to collaborate with agricultural product firms to develop and
commercialize products aimed at reducing food wastage. Being a
natural botanical extract, the CELEXT07 agent will readily
decompose in the environment and such agents are considered low
risk by pesticide regulators due to their natural origin.
Mr. Jean-Philippe Gravel, CEO of
Mondias Naturals Inc stated, "For the last 4 years Mondias has been
studying the properties of CELEXT07 as well as preparing for its
commercialization. We are now targeting partnerships for the
commercialization of natural products to bring the CELEXT07
botanical agent to the market in 2019." According to Allied
Market Research, the global fungicide product market had revenues
of $11 billion dollars in 2015 and is
expected to grow to approximately $17
billion dollars by 2022. Mr. Gravel added, "With its
commercialization and partnership strategy, Mondias intends to
become a key player in this fungicide market offering a natural
solution to the prevention of Grey Mold while helping stimulate
plant growth."
About Grey Mold
Grey Mold (Botrytis cinerea) is
a fungus that affects many plant species. It is well
known for its infections in wine grapes. In viticulture, it is
known as "botrytis bunch rot". The fungus affects more than
200 plant species and can result in serious economic losses to
both field and greenhouse grown crops. The fungus can infect
mature or senescent tissues, plants prior to harvest, or seedlings.
Horticultural crops include vegetables such as lettuce, broccoli,
and beans and small fruit crops such as grape, strawberry, and
raspberry.
About Mondias Natural Products Inc.
Mondias
specializes in the commercialization and development of evidence
based botanical products for the health care and bio agriculture
markets. The company is already selling both oral and topical
botanical agents to help manage unmet medical needs through Holizen
Laboratories, one of its divisions. Mondias is also developing
botanical based specialty fertilizers for use on household plants,
urban gardens, lawns, golf courses, nurseries or greenhouses in
collaboration with McGill's Faculty of
Agricultural and Environmental Sciences.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this
release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Company believes, expects or anticipates will
or may occur in the future (including, without limitation,
statements regarding potential acquisitions and financings) are
forward-looking statements. Forward-looking statements are
generally identifiable by use of the words "may", "will", "should",
"continue", "expect", "anticipate", "estimate", "believe",
"intend", "plan" or "project" or the negative of these words or
other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Company's ability to
control or predict, that may cause the actual results of the
Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include,
among other things, without limitation, the inability of the
Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company's
research and development strategies, the success of this joint
venture, the ability to obtain orphan drug status, the
applicability of the discoveries made therein, the successful and
timely completion and uncertainties related to the regulatory
process, the timing of clinical trials, the timing and outcomes of
regulatory or intellectual property decisions and other risks
disclosed in the Company's public disclosure record on file with
the relevant securities regulatory authorities. Although the
Company has attempted to identify important factors that could
cause actual results or events to differ materially from those
described in forward-looking statements, there may be other factors
that cause results or events not to be as anticipated, estimated or
intended. Readers should not place undue reliance on
forward-looking statements. While no definitive documentation has
yet been signed by the parties and there is no certainty that such
documentation will be signed. The forward-looking statements
included in this news release are made as of the date of this news
release and the Company does not undertake an obligation to
publicly update such forward-looking statements to reflect new
information, subsequent events or otherwise unless required by
applicable securities legislation.
www.mondias.ca
SOURCE Mondias Natural Products Inc.